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THE MEDICAL DEVICES EXCISE TAX (MDET) –
A MARKET-SPECIFIC VAT?
Richard T. Ainsworth
Andrew Shact
Gail Wasylyshyn
VATs flourish in complex, clearly defined markets. New York discovered this
when it converted its single-stage retail sales tax on hotel rooms, the Hotel Room
Occupancy Tax (HROT), into a multi-stage European-style Value Added Tax. The
statutory change was policy-driven and a direct response to increased market complexity.
New York began to experience HROT problems collecting the full transaction tax
when online room remarketers entered the supply chain, placing themselves between the
hotel (manufacturing the available rooms) and the (retail) customer1. While online
marketers were embedded in the supply chain their value was not in the tax base.2 The
impact on revenue was direct3.
The HROT VAT conversion demonstrates that moving to a multi-stage VAT can
(a) mitigate or eliminate losses attributable to supply-chain-fragmentation, (b) in a clearly
defined market where, (c) a single stage tax is imposed on (d) less than all supply chain
stages. In addition, where taxability at one supply chain stage is determined by actions in
a distant chain stage, adopting a VAT reduces complexity by making the tax transparent
and self-enforcing.
The Medical Devices Excise Tax (MDET) imposes as 2.3% excise tax on
manufacturers, producers or importers selling clearly identified medical devises under
Internal Revenue Code (IRC) §4191. The MDET, as conceived under proposed
regulations like the earlier HROT is a single stage transaction tax levied on one complex
1

The HROT is very much like a simple manufacturer’s tax although the technical taxpayer is the occupant,
not the hotel as it would be under a manufacturer’s tax. The inventory being produced (manufactured) is
vacant hotel rooms. The hotel sells occupancy rights to rooms and collects tax on the transaction. Rooms
that remain unoccupied are the bane of this industry. Online room remarketers solve these difficulties by
becoming involved in the last minute room rentals that might otherwise remain vacant. Even though they
added value to the supply chain with their “demand collection systems” the remarketers value not only
escaped tax, but the HROT’s structure allowed this value to be removed from what would have been the
hotel owner’s (manufacturer’s) tax base. Redesigning the HROT as a VAT New York closed this tax gap.
2
Essentially an online business that has no nexus with the taxing jurisdiction cannot be compelled to
collect tax on sales made within the State. See these arguments in: County of Nassau, NY v. Hotels.com et.
al. 594 F. Supp. 2d 251 (E.D.N.Y., 2007) (case dismissed because the county did not exhaust
administrative remedies); County of Nassau, NY v. Hotels.com et. al. 577 F.3d 89 (2nd Cir., 2009) (vacated
and remanded for failure to meet requirements for class certification under Fed. R. Civ. P. 23 because it is
not clear that all the class members imposed a hotel tax that was similar to the Nassau County hotel tax).
3
For a detailed HROT discussion as a VAT see: Richard T. Ainsworth, New York Adopts a VAT, 61 STATE
TAX NOTES 223 (July 25, 2011). See also: proposals to modify the retail sales tax in retail gasoline market
in Illinois and Michigan to deal with significant fraud issues by following the New York HROT example.
Richard T. Ainsworth, Michigan’s Industry-Specific VAT, 62 STATE TAX NOTES 441 (November 14, 2011).

1
Electronic
Electroniccopy
copyavailable
availableat:
at:https://ssrn.com/abstract=2086594
http://ssrn.com/abstract=2086594

MDET as a VAT
Ainsworth, Shact & Wasylyshyn
13 July 2012

supply chain stage in a clearly defined market. The major difference between MDET and
the former HROT is that MDET is a single-stage manufacturer tax while the HROT is a
single-stage retail tax residing at opposite ends in problematical supply chains.4
As a manufacturers excise tax, the MDET attempts to accomplish in the complex
medical device market what has been achieved in six other relatively simple commodity
markets (sport fishing equipment;5 archery equipment;6 coal;7 tires;8 gasoline guzzling
automobiles;9 and vaccines10). Difficulties are, however, expected in this market due to
the high-value role services and technology play in developing, selling, and distributing
these products.
The MDET, like the former HROT, would benefit from being recast as a marketspecific VAT. This paper explains why and how this can be achieved.
MDET
MDET has an affirmative and negative part. The affirmative aspect lies in IRC
§4191. The negative aspect is the related disconnection between §4191 and Code
sections that would have attached to it because the MDET appears in USC subtitle D
chapter 32. Both aspects need to be considered to understand the policy options open to
the Treasury during implementation.
MDET - The affirmative aspect under HCERA§1405(a)
The Health Care and Education Reconciliation Act of 2010 (HCERA)11, in
conjunction with the Patient Protection and Affordable Care Act (PPACA)12, introduced
the Medical Devices Excise Tax under HCERA§1405(a). The tax is effective for medical
devices sold after December 31, 2012. IRC§4191 states:
§4191 Medical devices
(a) In general
There is hereby imposed on the sale of any taxable medical device by the
manufacturer, producer, or importer a tax equal to 2.3 percent of the price for
which so sold.
(b) Taxable medical device
For purposes of this section—
(1) In general
4

Stated differently, the major HROT problem (coming at the supply chain’s end) was how to be sure all
the taxable value was included in the base, whereas the major MDET problem (coming as the supply chain
begins) is how to tax the full manufactured value with appropriate allowance for refunds based on
transactions with final consumers at the other supply chain end.
5
IRC §4161 including: fishing rods and fishing poles; fishing tackle boxes; electric outboard boat motors
6
IRC §4162 including: bows, quivers, broad heads, points and arrow shafts
7
IRC §4121 imposed on coal from mines located in the US sold by the producer
8
IRC §§4071-4073 imposed on bias ply or super ply tires, essentially any tire used on highway vehicles
9
IRC §4064 applicable to automobiles based on EPA determined fuel economy, model type, and model
year
10
IRC §§4131-4132 (sixteen specific vaccines are listed)
11
Pub. L., No. 111-152, 124 Stat. 1029, 1064-1065 (2010).
12
Pub. L., No. 111-148, 124 Stat. 119 (2010).
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The term ‘‘taxable medical device’’ means any device (as defined in
section 201(h) of the Federal Food, Drug, and Cosmetic Act) intended for
humans.
(2) Exemptions
Such term shall not include—
(A) eyeglasses,
(B) contact lenses,
(C) hearing aids, and
(D) any other medical device determined by the Secretary to be of
a type which is generally purchased by the general public at retail
for individual use.
The most challenging section within this short provision lies in §4191(b)(2)
because each item listed is a product exemption. There are three product specific
exemptions for eyeglasses, contact lenses and hearing aids with a fourth open-ended
exemption at §4191(b)(2)(D). Congress intended the fourth exemption to be regulatory
driven further product exemptions.
In other words, Congressional intent was that the Treasury would compose a list
of other qualified medical device products that met the standard set out in the statute.
These were to be products “of a type … generally purchased by the general public at
retail for individual use”13.
MDET – The first negative aspect underHCERA§1405(b)(1)
This HCERA section makes four of the six traditional entity/use exemptions that
are generally available to manufacturer taxes under the IRC inapplicable to the MDET14
by expressly stating:
Section 4221(a) of the Internal Revenue Code of 1986 is amended by
adding at the end the following new sentence:
‘‘In the case of the tax imposed by section 4191, paragraphs (3),
(4), (5), and (6) shall not apply.’’
The removed exemptions are for supplies purchased for use on vessels and
aircraft15, items State or Local governments purchase for their exclusive use16, items that
13

The Joint Committee on Taxation is very clear that a product exemptions list is envisioned. The same
language can be found in two different JCT documents:
It is anticipated that the Secretary will publish a list of medical device classifications [a
footnote specifies that classifications like those found in Title 21 of the Code of Federal
Regulations, Parts 862-892 are to be emulated] that are of a type generally purchased by
the general public at retail for individual use.
Joint Committee on Taxation, General Explanation of Tax Legislation Enacted in the 111th Congress
(JCS-2-11), March 2011, at 366 & n. 986. See also Joint Committee on Taxation, Technical Explanation of
the “Revenue Provisions of the Revenue Reconciliation Act of 2010,” as amended, in combination with the
“Patient Protection and Affordable Care Act,” JCX-18-10 (March 2010) at 138 & n. 296.
14
The remaining two traditional entity / use exemptions applicable to the MDET are the: (1) exemption
for a purchaser who will use a medical device for further manufacture, or resold to a second purchaser for
further manufacture under §4221(a)(1), and (2) exemption for export, or sale to a second purchaser for
export under§4221(a)(2).
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non-profit educational organizations purchase for their exclusive use17, and items
purchased by qualified blood collector organizations for use in collecting, storing or
transporting blood18.
Entity exemptions are relatively easy to work if there is a direct relationship
between the exempt entity and the manufacturer. They are more complicated when a use
requirement is linked to the entity’s status. Each §4221(a) exemption is a combined
entity/use exemption.
The more remote an exempt party is from the party paying the tax, the more
difficult it is to make entity exemptions work in excise taxes. Regulations issued under
IRC §4221(a) make it clear that this principle is well understood. Three standard excise
tax exemptions (sales to State and local governments, sales for nonprofit educational
purposes, and sales to vessels and aircraft) require a direct relationship between the
exempt party and the manufacturer for the exemption to be honored. These exemptions
are not allowed to pass through a distributor19 and both the exempt party and
manufacturer must register with the IRS20.
Manufactures taxes are averse to passing an exemption certificate through
multiple parties in a commercial chain. Other than a limited exception for export sales
where three parties are allowed in the exemption chain21, all exemptions are direct.
Enforcement involves denying an exemption if the manufacturer has “reason to believe
that the article sold was not actually intended for the exempt purpose indicated by the
purchaser”22.
15

§4221(a)(3)
§4221(a)(4)
17
§4221(a)(5)
18
§4221(a)(6)
19
See for example, Treasury Regulation §48.4221-5(a) indicating that the State and local government
exemption under §4221(a)(4) is only available where the manufacturer makes the sale directly to the State
or local government for its exclusive use. “No sale may be made tax free to a dealer for resale to a State or
local government for its exclusive use, even if it is known at the time of sale by the manufacturer that the
article will be resold.” The exact same language can be found in Treasury Regulation §48.4221-6(a)
requiring the manufacturer to sell directly to nonprofit educational organizations to qualify for the
exemption under §4221(a)(5). The same is true under Treasury Regulation §48.4221-4(a) tax-free article
sales for purchaser use as supplies for vessels or aircraft.
20
See for example, when making sales to vessels or aircraft both the manufacturer and the purchaser are
required to be registered with the IRS. [Treasury Regulation §48.4221-4(d)(1)(i)]. In cases, however,
where one or both parties are not registered such as foreign owned vessels or aircraft the manufacturer must
possess “prior to or at the time of sale” a properly executed exemption certificate as prescribed under
Treasury Regulation §48.4221-4(d)(2)(iii). In cases involving occasional sales, a separate exemption
certificate must be obtained for each order. In the case involving frequent orders, a single exemption
certificate will suffice and be valid for up to three years. [Treasury Regulation §48.4221-4(d)(2)(ii)]
21
See Treasury Regulation §48.4221-3(a)(1) indicating that the chain cannot include a “third purchaser for
export.” In cases where the second purchaser will export, “the manufacturer must have in his possession a
statement from the vendee to whom the manufacturer sold the article stating that the article was in fact
exported in due course by the vendee, or was sold to another person who in due course exported the article.
The statement must state what evidence is available to establish that the article was in fact exported in due
course prior to use or further manufacture, and prior to resale in the United States other than for export.”
22
Treasury Regulation §48.4221-1(b)(3).
16
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Entity/use exemptions are simply not workable under the MDET if Congress
intends that the entity qualifying for the exemption is a retail consumer and if “individual
use” is required. The exemption chain would be too long. It would be too difficult to
pass a certificate from the consumer all the way back to the manufacturer. On the other
hand, product exemptions do not have these problems. This is most likely the reason
that the three MDET statutory exemptions are product exemptions.
MDET – The second negative aspect under HCERA§1405(b)(2)
Single stage transaction taxes that allow entity/use exemptions create
overpayment situations so refund procedures are needed. This is common in exports,
which makes administering the tax cumbersome. For example, if a manufacturer collects
tax on a vaccine sold under §4131 but the purchaser or the next buyer exports the article
in a manner qualifying for exemption under §4221(a)(2), then the tax the manufacturer
already paid is overpaid. A refund is available under §6416(b)(2)(A) if the Treas. Reg.
§48.6416(b)(2)-2 requirements are met.
Thus, when MDET was adopted without the four traditional entity/use
exceptions, four companion provisions dealing with overpayments were disassociated
from the MDET23 by stating:
Section 6416(b)(2) of such Code is amended by adding at the end the
following:
‘‘In the case of the tax imposed by section 4191, subparagraphs
(B), (C), (D), and (E) shall not apply.’’
REGULATORY COMPROMISE
The IRS published Notice 2010-89 24 on December 27, 2010 requesting
comments on the MDET’s implementation and administration. Shortly thereafter,
proposed regulations were issued25 and a public hearing was held on May 16, 2012.
The Proposed Regulations represent a significant compromise in what Treasury
perceived to be the major MTEC issue26, how should the retail exemption be drafted?
There are at least four other major issues that need to be resolved before regulations are
finalized but on this point there is a compromise. The question is Should the regulations
present a comprehensive product exemptions list or should the retail exemptions be
drafted in an entity/use manner?
What happened was a mixture between both. The medical device industry
persuaded the Treasury that a comprehensive product exemptions list was not

23

§1405(b)(2)
2010-52 IRB 908
25
Proposed Treasury Regulation §§48.4919-1 and 48.4919-2; Fed. Reg. Vol. 77, No. 25, at 6028 (February
7, 2012).
26
There are numerous additional issues. The four most important are considered infra and Treasury will
need to address in the final regulations.
24
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workable27 nor based on past practice was an entity/use exemption workable. To
institute an entity/use exemption Treasury would need to define a (generalized) final
consumer and also define a (generalized) consumer’s personal use28. This approach is
also unworkable29.
27

Industry groups, law firms, and accounting firms, opposed a product exceptions list in the regulations.
The IRS was persuaded. See for example Donald T. Rocen & Marc J. Gerson (Miller & Chevalier), Letter:
Comments to Notice 2010-89, 2010 I.R.B. 908 (March 28, 2011) at 4-5 indicating that the product
exemption approach would be “difficult (if not impossible)” to carry out:
Although the JCT General Explanation anticipates that the IRS will publish a list of Food
and Drug Administration ("FDA") medical device classifications that qualify for the
retail exemption, it is respectfully suggested that as a practical matter such a list will be
difficult (if not impossible) for the IRS to develop, update and administer, particularly in
light of the substantial number and differentiation of medical devices and the frequency
of product innovation in the medical device industry. Furthermore, such a list may not
sufficiently identify which taxable medical devices properly qualify for the exemption,
since a single medical device classification may encompass a large number and type of
distinct medical devices some of which are "generally purchased by the general public at
retail for individual use" and some of which are generally purchased by health care
institutions such as hospitals.
This observation was reinforced by Christopher J. Ohmes & Michael Udell (Ernst & Young), Making Sense
of the New Excise Tax on Medical Devices, 133 TAX NOTES1015, 1016-17 (November 21, 2011). Ohmes
and Udell present specific data on the difficulties the IRS would face with a product exemption regulatory
approach:
Although Congress envisioned that this retail sale exclusion would be implemented
through an item list that may be impractical. There are more than 5,630 FDA product
codes for medical devices. Eyeglasses, contact lenses, and hearing aids, which are tax
exempt by statute, constitute 25 of them. Thus, Treasury and the IRS would need to
address more than 5,600 device types to promulgate a list. We estimate that of those,
roughly 266 may be eligible for the retail sales exclusion depending on how the limits of
the exclusion are defined. No matter how the definitional questions are resolved, to
derive a list, Treasury and the IRS will need a great deal of information that is not
publicly available for all those device types. Moreover, even if the data were available, it
would take a significant amount of effort to characterize the data by the ‘‘general
public,’’ ‘‘individual use,’’ and ‘‘retail’’ filters and then apply whatever definition of the
phrase ‘‘generally sold’’ is to be used.
All through this process the medical device industry was making similar comments. See for example
AdvaMed (the Advanced Medical Technology Association) opposition per Stephen J. Ubl, Letter
responding to Notice 2011-89’s request for comments specifically on §4191(b)(2)(D), March 22, 2011, at 5
– 10, followed up by an additional Letter: HIGHLIGHTS: AdvaMed Comments on the Medical Device Tax
(March 3, 2012) at 2, and finally Letter: AdvaMed Comments on Implementation of Medical Devices Excise
Tax Provisions of the Affordable Care Act (May 3, 2012) at 1, which thanks the IRS for rejecting the
product exemption approach in the proposed regulations:
At the outset, AdvaMed appreciates the consideration given by Treasury to the
complexity of the medical device industry. … [and] for determining whether a device is
exempt by reason of the retail exclusion [for taking] … a thoughtful approach that took
into account the comments received in response to IRS Notice 2010-89, in particular that
a "list" not be the mechanism to define those devices exempt under the retail
exemption in the dynamic and diverse medical device market. (emphasis added)
28
A. Paige Keener (Novo Nordisk), Letter: Comments on REG-113770-10, Taxable Medical Devices,
(May 7, 2012) at 3, available at TAX ANALYSTS, Doc 2012-9994 or 2012 TNT 93-98 (agreeing with the
IRS that a market data approach if applied overall to the retail exemption would not be workable, however,
suggesting that when market data is available then it could be used effectively).
29
This approach would entail regular retail medical device marketplace national surveys. See: Stephen J.
Ubl, Letter: AdvaMed Comments on Implementation of Medical Device Excise Tax Provisions of the
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Product exemptions are set out in a regulatory “safe harbor”30 list that responded
favorably to many public comments the Treasury received. The safe harbor list is:
1. Devices included in the FDA’s online IVD Home Use Lab Tests (Over-theCounter Tests) database,31
2. Devices that are described as “OTC” or “over the counter” devices in the
relevant FDA classification regulation heading.
3. Devices that are described as “OTC” or “over the counter” devices in the
FDA’s product code name, the FDA’s device classification name, or the
“classification name” field in the FDA’s device registration and listing database,32
4. Devices that qualify as durable medical equipment, prosthetics, orthotics, and
supplies, as described in Subpart C of 42 CFR Part 414 (Parenteral and Enteral
Nutrition) and Subpart D of 42 CFR Part 414 (Durable Medical Equipment and
Prosthetic and Orthotic Devices), for which payment is available on a purchase
basis under Medicare Part B payment rules, and are:
(a) “Prosthetic and orthotic devices,” as defined in 42 CFR 414.202, that do
not require implantation or insertion by a medical professional;
(b) “Parenteral and enteral nutrients, equipment, and supplies” as defined in
42 CFR 411.351 and described in 42 CFR 414.102(b);
(c) “Customized items” as described in 25 CFR 414.224;
(d) “Therapeutic shoes,” as described in 42 CFR 414.228(c); or
(e) Supplies necessary for the effective use of DME, as described in section
110.3 of chapter 15 of the Medicare Benefit Policy Manual (Centers for
Medicare and Medicaid Studies Publication 100-02).
The entity/use exemption formulation in the Proposed Regulation is unusual.
The reason for odd draftsmanship here is that the normal approach for having the exempt
entity (retail consumer) issue an exemption certificate that the taxable party
(manufacturer) will use to remove the tax is nearly impossible to design.
Rather than clearly identifying an entity and a clearly specifying a use the
regulation relies on a speculative “facts and circumstances” test. The manufacturer
applies this two-pronged “test” as it examines the specific device’s nature. The two-part
test has affirmative and negative aspects. The first (inclusive) test identifies factors that
determine if an item is “regularly available for purchase and use by individual
consumers” while the second (exclusionary) test determines if a device is “primarily for
use in a medical institution or office or by a medical professional.”

Affordable Care Act, May 3, 2012) at 17 (discussing applying Revenue Ruling 80-273, 1980-2 C.B. 315 to
the medical device area and indicating that the 75% rule should be applied generally for determining the
constructive price unless it can be shown on a industry-wide basis that a lower percentage should apply). It
would be similar to the way that Michigan and Illinois determine values for imposing the sales tax on retail
gasoline. [See: Richard T. Ainsworth, Michigan’s Industry-Specific VAT, 62 STATE TAX NOTES 441
(November 14, 2011)].
30
Proposed Treasury Regulation §§48.4919-2(b)(2)(iii).
31
Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfIVD/Search.cfm
32
Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm
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The device qualifies for the retail exemption if it passes the first test but is not
picked up under the second test. There are no exemption certificates, no tracing actual
purchase/use,33 and no provision for overpayments based on a specific consumer’s
transaction.34
UNANSWERED QUESTIONS
There are several unanswered questions in the proposed regulations that were
aired at the May 16th public hearing. While easy answers do not appear likely given the
way the regulations are currently drafted, some answer will be needed before the tax goes
into effect on January 1, 2013. The four most troubling questions relate to:
Double taxation - Do the “further manufacturing” operating rules and the
pervasive kits, dual-purpose devices, and combined products in the medical
device market create a situation where double taxation is likely?
Related party pricing - Will the traditional constructive price rules apply in the
medical devices area, most notably the 75% valuation safe harbor rule under
Revenue Ruling 80-27335? Given the related party transactions typical in the
medical device market and the probability that transactions may be structured
among related parties to reduce exposure to the MDET, this issue could impact
the revenue raised under this tax.
Title passage - How should the Chapter 32 title passage rules be incorporated into
the MDET? While Treasury Regulation §48.0-2(a)(5) specifies that title must
pass for a sale to be taxable, critical value added services and software may not be
included if this is the dominant rule in place for the MDET.
Objective valuation - Can the MDET depart from the objective valuation standard
utilized in the Chapter 32 manufacturers excise taxes, or can subjective valuation
be used instead? This change would align the MDET more closely with
normative accounting standards, ease compliance costs, and make the tax fairer
when medical devices charitable contributions are considered.
Unanswered Question (1) – Double Taxation

33

See: AdvaMed (the Advanced Medical Technology Association) Stephen J. Ubl, Letter responding to
Notice 2011-89’s request for comments specifically on §4191(b)(2)(D), March 22, 2011, at 18 available at
TAX ANALYSTS, Doc 2011-6160 or 2011 TNT 58-12 (asking for a credit mechanism in MDET, but one
that does not require device-by-device tracing taxes paid in the manufacturing chain).
34
An overpayment might be made though the manufacturer’s misjudgment in applying the facts and
circumstances tests. This could be handled in a traditional audit. Overpayments are anticipated in
circumstances where a primary manufacturer collects tax when it sells to a secondary manufacturer such as
a kit assembler. A credit or a refund claim can be made under §6416(b)(3), and Treasury Regulation
§48.4221-2(b).
35
1980-2 C.B. 315
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Manufacturing taxes are premised on a single tax assessment, with the time and
place for assessment taking place when the manufacturing phase ends36. As a result, no
tax is due when there is further manufacturing within the supply chain. Thus, IRC
§4221(a) sets out a further manufacture exception for enterprises that are manufacturers
yet are not the last manufacturer in the supply chain. Congress intends these rules to
apply to the MDET37.
Under regulations prescribed by the Secretary, no tax shall be imposed
under this chapter … on the sale by the manufacturer … of an article –
(1) for use by the purchaser for further manufacture, or resale by the
purchaser to a second purchaser for us by such second purchaser in
further manufacture, (emphasis added)
The term “manufacturer” has a regulatory definition in part 48 relating to all
excise taxes imposed under IRC chapters 31 and 32. The definition is broadly drafted,
and “unless otherwise expressly indicated”38 applies to the MDET. It states:
The term “manufacturer” includes any person who produces a taxable
article from scrap, salvage, or junk material, or from new or raw material,
by reprocessing, manipulating, or changing the form of an article or by
combining or assembling two or more articles. The term also includes a
“producer” and an “importer.”39
The operative principle underlying manufacturers’ taxes is that by applying this
definition link-by-link throughout a supply chain, each party can determine if they are the
person on whom the tax is imposed. One simply asks am I: (1) a manufacturer and (2)
the last manufacturer.
If the supply chain is a simple one, then all a manufacturer needs to do is to assess
how one’s customers intend to use the provided supply40. The most problematical part in
36

Jill Witter (Novation), Letter: Comments to REG-113770-10 (May 7, 2012) at 4, available at TAX
ANALYSTS, Doc 2012-10986 or 2012 TNT 100-17, Company Suggests Changes to Proposed Regulations
on Medical Device Excise Tax (“Generally, the manufacturer is determined by looking at each party is a
particular supply chain and the last party to perform significant transformative activities on a particular
product that rises to the level of manufacturing is the one on whom the tax is imposed.”)
37
Joint Committee on Taxation, General Explanation of Tax Legislation Enacted in the 111th Congress,
JCS-2-11 (March 2011) at 367. (“The present law manufacturers excise tax exemptions for further
manufacture … apply to tax imposed under this provision …” See also: Joint Committee on Taxation,
Technical Explanation of the “Revenue Provisions of the Revenue Reconciliation Act of 2010,” as
amended, in combination with the “Patient Protection and Affordable Care Act,” JCX-18-10 (March 2010)
at 138.
38
Treasury Regulation §48.0-2(a)
39
Treasury Regulation §48.0-2(a)(4)(i) (emphasis added), referenced by Prop. Treasury Regulation
§48.4191-1(c)
40
In a relatively linear supply chain this is not a difficult task. Revenue Ruling 79-192, 1979-1 CB 340
(modifying an automobile truck chassis – shortening the wheel base – to permit use in street sweeping
chassis is subsequent manufacture; but using the chassis without modification is not); Revenue Ruling 67374, 1967-2 CB 376 (combining a conventional fishing reel with a power unit constitutes further
manufacture because an electric fishing reel is created); Priv. Ltr. Rul. 84-030-36 (Oct. 18, 1983)
purchasing individual components from various distributors and then gluing them together to make a
finished arrow is subsequent manufacture).
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applying this definition has always been the final disjunctive phrase “or by combining or
assembling two or more articles.” The question raised is whether this provision requires
that something more needs to be done (than mere packaging or repackaging) to be a
manufacturer41?
Considerable authority indicates that combining or assembling must result in a
transformation, either in form or function, so that a new taxable article is created. Cases
dealing with packaging mascara42, replacement parts for automobiles43, and rulings
dealing with packaging rear view truck mirrors are all consistent in this regard44.
This authority however, does not fit well with the MDET. IRC §4191(b)(1) takes
away the flexibility previously enjoyed when applying these rules by defining a “taxable
medical device” as a “device” under Federal Food, Drug, and Cosmetic Act §201(h). As
a result, we are not applying a flexible legal test but rather a rigid statutory test that relies
on an externally produced list of qualifying items. The most immediate problem this
creates involves medical kits45.
Under §201(h), the FDA lists medical kits as a new or different “medical device”,
separate and distinct from the scalpel (for example) included in the kit. The tax
consequence under §201(h) are that the scalpel manufacturer is not subject to MDET for
scalpels sold to kit-makers if these scalpels are combined or assembled into medical kits.
The kit-maker, on the other hand, is a subsequent manufacturer subject to tax on the full
kit price rather than the price for the individual medical devices contained within the kit.
This kit-maker, however, would not be a subsequent manufacturer if it re-sold the
scalpel absent the kit. In this case, it is the scalpel manufacturer who is the last
manufacturer and subject to tax.
To make this application very clear, the proposed regulations expressly adds kit
assembly to the further manufacturing regulations at §48.4221-2(b)(3)46. At this point,
the Medical Device Manufacturers Association (MDMA) objects, because:
This unnecessarily over-inclusive approach will result in imposition of the
excise tax on items that Congress never intended to be taxable and will
effectively result in double taxation of certain kits and combination
devices … many kits consist not only of devices but also pharmaceuticals
41

There have been several Service rulings indicating that mere packaging is not manufacturing. Revenue
Ruling 72-561 (“the mere association of two or more articles in a single container [does not] result in the
packager becoming a manufacturer”); G.C.M. 34332 (Aug. 7, 1970) (“mere packaging together of
automobile parts, general purpose items, or automobile parts and general purpose items in a kit which is
intended to be sold primarily for use in the repair of automobiles does not, without more, constitute the
manufacture of a new taxable article).
42
Williams v. Harrison, 110 F.2d 989, 994 (7th Cir. 1940).
43
Sealed Power Corp. v. Kavanaugh, 81 F. Supp. 459 (E.D. Mich. 1948).
44
Revenue Ruling 72-561, 1972-2 C.B. 548
45
In general, a kit is two or more different medical devices, or a combination of medical devices and other
items, that are packaged together. When a kit is listed as a device with the FDA pursuant to FDA
requirements, the proposed regulation would impose tax on the entire price of the kit.
46
Treasury Regulation §48.4221-2
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and other goods not subject to the tax that add substantially to the cost of
the kits.47
The MDMA explained at the May 16th hearings that the further manufacturing
exception does not work in the MDET due primarily to the market itself and the medical
device manufacturing process:
[T]he proposed regulations fail to take into account the unique nature and
use of many medical device technologies. Until now, excise taxes were
only imposed on commodity products. This is likely due to the fact that
such products are easily identifiable and, the affected industries are
involved in manufacturing of less complex products designed for a readily
apparent use. In contrast, the medical devices which would be taxed under
the proposed regulations are virtually all scientifically complex, and may
be designed for a disparate range of uses48.
Although theoretically assuring a single tax (only the further manufacturer is
actually liable for tax), commentators contend that logistical issues will make double
taxation a near certainty. According to BayCare Health System,
 Under the MDET device manufacturers will be inclined to tax all sales to kit
makers, because following up with all customers to determine whether or not
there is intent for further manufacturing would be too difficult49.
 Kit-making customers that purchased medical devices (some for use in kits and
some for direct re-sale) might not know in advance the number of kit that would
be made. To get the tax right will require an internal tracking system and
retrospective reporting50.
Standard hospital operations present precisely this problem because hospitals
purchase kits from third parties along with internally assembling kits51. The Federation
of American Hospitals believes that at a minimum a hospital’s kit assembly should be a
safe harbor exception because “… kit assembly and sterilization [of included devices] do

47

Medical Device Manufacturers Association, Letter (May 7, 2012) at 2, available at TAX ANALYSTS, Doc
2012-9990 or 2012 TNT 93-94 Manufacturers Group Suggests Narrowing Scope of Proposed Regulations
on Medical Device Excise Tax.
48
Comments of Thomas Novelli at Public Hearing on Proposed Regulations 26 CFR Part 48 “Taxable
Medical Devices” [REG-113770-10] (May 16, 2012) unofficial transcript available at TAX ANALYSTS,
Doc 2012-2232 or 2012 TNT 24-20.
49
Federation of American Hospitals (and others), Letter: Notice of Proposed Rulemaking and Notice of
Public Hearing on Taxable Medical Devices (77 Fed. Reg. 6.028 [Feb. 7, 2012]) at 4 indicating that “as
purchasers of medical devices, hospitals and group purchasing organizations are concerned that medical
device companies will eventually pass through this entire tax to their customers”)
50
Judith P. Lipscomb (BayCare Health System) Letter: Comments on Proposed Rulemaking on Taxable
Medical Devices (REG-113770-10) at 2, available at TAX ANALYSTS, Doc 2012-9987 or 2012 TNT 93-91,
Health System Raises Concerns About Double Taxation Under Proposed Regulations on Medical Device
Excise Tax
51
Federation of American Hospitals (and others), Letter: Notice of Proposed Rulemaking and Notice of
Public Hearing on Taxable Medical Devices (77 Fed. Reg. 6.028 [Feb. 7, 2012]) at 9.
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not cause a hospital to be a ‘manufacturer’ (or ‘importer’) subject to the medical device
tax”52.
The Academy of Dentistry has similar concerns. The further manufacture rule
would “increase the cost of care by taxing certain devices twice and taxing items that are
not medical devices.”53 Cardinal Health, an enterprise that assembles four million kits
per day for delivery to over 60,000 locations, suggests that the correct answer is to
exempt all kits in the safe harbor provision54.
Conclusion – Unanswered Question (1)
It is not clear how the IRS will respond because there are several revenue and
policy implications in the answer to the double taxation issue:
Revenue: The further down the commercial chain the MDET goes before it
reaches a final manufacturer, the more revenue it will produce. Double taxation is very
likely if the rules are difficult to interpret and there is no prohibition on passing through
the tax55. Businesses will resolve these ambiguities by taxing transfers and passing the
burden on, even though a subsequent party may tax the same transfer again.
Policy: Determining who is a manufacturer based primarily on the FDA’s medical
devices listing under §201(h) is inconsistent with the traditional thrust of manufactures
excise taxes which is to apply conceptual legal tests.
Unanswered Question (2) – Related Party Pricing
The MDET is imposed at 2.3% on the price for which a taxable medical device is
sold with the price defined in IRC §4216 and Treasury Regulations §§48.4216(a)-1
through 48.4216(e)-356.
The proposed regulations indicate that there should be a “… basic sales price
[that] assume[s] that the manufacturer sells the taxable article in an arm’s length
transaction (that is, in a transaction between two unrelated parties) to a wholesale
distributor that then sells the taxable article to a retailer that resells to consumers.”57 The
basic sales price presumes a traditional manufacturer-wholesaler-retailer-consumer
marketplace. In cases where the basic sales price is not available, a constructive price
will be determined, as an exception.
52

Id., at 8
Academy of General Dentistry (and others), Letter: Internal Revenue Service Notice of Proposed
Rulemaking, Taxable Medical Devices REG-113770-10 (May 7, 2012) at 4, available at TAX ANALYSTS,
Doc 2012-9985 or 2012 TNT 93-89, Dentistry Groups Comment on Proposed Regs on Medical Device
Excise Tax
54
Lloyd Fort (Cardinal Health), Letter: Proposed Taxable Medical Device Excise Tax Regulations (May 7,
2012) at 3, available at TAX ANALYSTS, Doc 2012-9988 or 2012 TNT 93-92, Medical Products Maker
Suggests Changes to Proposed Regulations on Medical Device Excise Tax.
55
See: David Hawkins, HR 3509, HARVARD BUSINESS SCHOOL CASE STUDY, N9-111-056 (Rev. December
1, 2010) a business school note prepared as the basis for class discussion concerning accounting issues that
would allow or prevent the pass-through of the MDET to customers.
56
Proposed Treasury Regulation § 48.4191-1(b)
57
Proposed Treasury Regulation § 48.4191 (preamble)
53
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The reality is, in the MDET, the exception will be the rule. The way the medical
device market is structured, the price upon which the MDET is based will almost always
be determined under the Treasury Regulation §48.4216(b)-1 constructive price rules.
America’s Blood Centers observes:
[V]irtually all of the medical device tax is likely to be determined based
on constructive prices because very few medical devices are sold by
manufacturers to wholesalers that sell to retailers that sell to end users.58
Rocen and Gerson agree. The standard distribution network in this market
segment will compel most manufacturers to determine the tax base through
constructed prices because almost all manufacturer sales will be made to related
parties.
It is our understanding that members of the medical device industry
frequently utilize a network of affiliated corporations within their
respective U.S. consolidated groups to manufacture, import and distribute
taxable medical devices both domestically and internationally. Although
the structure of these networks may vary, it is our understanding these
networks typically involve a number of intercompany transactions before
the medical devices are sold or leased to the ultimate customer, whether it
be a hospital or an individual.59
The medical device industry is exceedingly top-heavy. Although the Medical
Device Manufacturers Association (MDMA) observes that 80% to 98% of the medical
device manufacturers swept up in the MDET will be small businesses60, 86% of the $20
billion the MDET is expected to generate over ten years will come from the ten largest
firms61. Thus, even though the MDET will be a considerable administrative burden for
numerous companies, the government’s revenue will come primarily from the largest
publicly traded multi-entity groups62.

58

Jim L. MacPherson (American’s Blood Centers) Letter: REG-113770-10 – Notice of Proposed
Rulemaking on Taxable Medical Devices (May 7, 2012) at 3, available at TAX ANALYSTS, Doc 2012-9984
or 2012 TNT 93-88, Blood Center Comments on Proposed Regulations on Medical Device Excise Tax.
59
Donald T. Rocen & Marc J. Gerson (Miller & Chevalier), Letter: Comments to Notice 2010-89, 2010
I.R.B. 908 (March 28, 2011) at 7, available at TAX ANALYSTS, Doc 2011-6537 or 2011 TNT 61-28.
60
Comments of Mark B. Leahey (Medical Device Manufacturers Association), Letter on Proposed
Regulations (REG-113770-10) at 2 (May 7, 2012) available at TAX ANALYSTS, Doc 2012-9990 or 2012
TNT 93-94 Manufacturers Group Suggests Narrowing Scope of Proposed Regulations on Medical Device
Excise Tax
[t]he medical technology industry is comprised primarily of small businesses.
Approximately 80% of medical technology companies have fewer than 50 employees,
and 98% have fewer than 500 employees.
61
Staff of Massachusetts Medical Devices Journal, Medical device tax would mostly hit the biggest firms,
MEDCITY NEWS, March 24, 2010, http://www.medcitynews.com/2010/03/medical-device-tax-wouldmostly-target-the-biggest- companies/.
62
Id., listing the top 10 firms as: Medtronic Inc., Baxter International Inc., Johnson & Johnson, Boston
Scientific Corp., Stryker Corp., St Jude Medical Inc., Agilent Technologies, Inc., Beckman Coulter, Inc.,
C.R. Bard, Inc., and Kinetic Concepts, Inc.
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Tax planning will give rise to two common fact patterns. Either (a) a further
manufacturer will sell the medical device within an affiliated group (involving several
intercompany transactions) to an end user at retail, or (b) the medical device will be sold,
and re-sold in a series of intra-group transactions with the tax due on a related party
internal transfer. The first structure takes advantage of Revenue Ruling 80-273. The
second structure’s advantage is that valuable software can be added to a device outside
the MDET’s ambit.
The attractiveness in Revenue Ruling 80-273 is its simple clarity and tax-base
reducing attributes63. It applies in cases where a manufacturer makes sales at retail64 but
the same or similar articles are not sold to wholesale distributors65. This is the fact
pattern that Rocen and Gerson (and several other commentators66) asked the Service to
specifically address and to place in examples67. Unfortunately, the Treasury did not
accept the invitation.
If shown to apply in the medical device area, Revenue Ruling 80-273 would deem
the devices’ tax price to be 75% of the price the customer was actually charged. The
holding is:
The constructive sale price for computing the taxes imposed by IRC
§§4061(b)(1), 4161(a), 4161(b) and 4181, where the articles are sold at
retail by manufacturers, producers, or importers who do not sell like
articles to wholesale distributors, is 75 percent of the actual selling price
after taking into account the adjustments provided by §4216(a) unless it
can be shown on an industry-wide basis that a lower percentage should
63

This is a fact pattern that fits into IRC§ 4216(b)(1)(A) where the tax “shall … be computed on the price
for which such articles are sold, in the ordinary course of trade, by manufacturers or producers thereof, as
determined by the Secretary”
64
A “retail sale” is the “sale of an article to a purchaser who intends to use or lease the article rather than
sell it.” [Treasury Regulation §48.4216(b)-1(c)(1)] In the MDET context this would be (for example) the
magnetic resonance imaging (MRI) equipment sales to a hospital of doctor’s office
65
A “wholesale distributor” is defined as “a person engaged in the business of selling articles to persons
engaged in the business of reselling such articles.” [Treasury Regulation §48.4216(b)-1(c)(3)]
66
See: Philip Albert (Medtronic), Medtronic, Inc. Comments on Implementation of Medical Device Excise
Tax Provisions of the Affordable Care Act – REG-113770-10 (May 4, 2012) at 37, available at TAX
ANALYSTS, Doc 2012-9991 or 2012 TNT 93-95 Medtronic Comments on Proposed Regulations on
Medical Device Excise Tax. Also see: Stephen J. Ubl (AdvaMed), AdvaMed Comments on Medical Device
Excise Tax (March 22, 2011) 15, available at TAX ANALYSTS, Doc 2011-6160 or 2011 TNT 58-12.
67
Donald T. Rocen & Marc J. Gerson (Miller & Chevalier), Letter: Comments to Notice 2010-89, 2010
I.R.B. 908 (March 28, 2011) at 7-8, available at TAX ANALYSTS, Doc 2011-6537 or 2011 TNT 61-28.
For example, in a representative structure, a taxpayer will utilize a number of
affiliated corporations, including (i) a manufacturing/importing corporation
("Manufacturing") that manufactures and imports taxable medical devices, (ii) a services
corporation ("Services") that provides shared corporate services, and (iii) a sales/leasing
corporation ("Sales") that sells and leases the medical devices to the ultimate customer.
Given the prevalence of these types of distribution networks in the medical
device industry, we respectfully suggest that the guidance issued under Section 4191
provide illustrative examples with respect to a variety of transactions, including not only
those involving intercompany sales through a series of affiliated corporations as
illustrated above
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apply. No further adjustments under §4216 are allowable. The
manufacturer's cost is not to be a factor in determining the constructive
sale price.
Intra-group tax - The Chapter 32 excise tax rules are applied on a separate entity
rather than affiliated group basis, even though requests have been made to allow MDET
reporting on this basis68. Because MDET applies to transactions between affiliated group
members69, taxpayers have some opportunity to control the tax point.
Rocen and Gerson make this point when they suggest an answer to the
hypothetical proposed (supra note 67) involving three affiliated group members
(“Manufacturing,” “Services,” and “Sales”) transferring a medical device among
themselves before selling it to an end user. Rocen and Gerson indicate:
[the] illustrative example [should] confirm that (i) the sale of the medical
devices from Manufacturing to Services is subject to the medical device
excise tax because this constitutes a sale by the "manufacturer, producer or
importer,” and (ii) the subsequent sales of medical devices from Services
to Sales and from Sales to the ultimate customers are not subject to the
medical device excise tax.70
The critical point is that the “Services” value added is not taxed because the value
provided by “Services” is not an independently listed medical device under Federal Food,
Drug, and Cosmetic Act §201(h)71. “Services” is not engage in further manufacturing
nor combining or assembling its value added with another taxable medical device.

68

David Fisher (Siemens Healthcare) comments at Public Hearing on Proposed Regulations 26 CFR Part
48 “Taxable Medical Devices” [REG-113770-10] (May 16, 2012) unofficial transcript available at TAX
ANALYSTS, Doc 2012-2232 or 2012 TNT 24-20.
Therefore, we recommend that the regulations provide an option that would permit a U.S.
corporate group to designate a common parent to report the device tax on behalf of all of
its U.S. affiliates on a single Form 720 and to make a single semi-monthly tax deposit.
Philip Albert (Medtronic), Letter: Comments on Implementation of Medical Device Excise Tax Provisions
of the Affordable Care Act – REG-113770-10, (May 4, 2012) at 4-5, available at TAX ANALYSTS, Doc
2012-9991 or 2012 TNT 93-95 Medtronic Comments on Proposed Regulations on Medical Device Excise
Tax.
In order to reduce this burden [of compliance by multiple entities in a single group],
while having no impact on the actual taxes collected by the US Government, Medtronic
requests that the Treasury Department update the excise tax payment requirements to
allow companies within a controlled group of companies, under §1563, to have one entity
make the required excise tax deposits and file the quarterly excise tax return on behalf of
all controlled group members, if so elected. … All data will be captured by the paying
entity with details as to each controlled group member's excise tax responsibility.
69
IRC §§4216(b)(3) and 4216(b)(4) apply constructive sales price rules to transactions between members
of the same affiliated group.
70
Donald T. Rocen & Marc J. Gerson (Miller & Chevalier), Letter: Comments to Notice 2010-89, 2010
I.R.B. 908 (March 28, 2011) at 8, available at TAX ANALYSTS, Doc 2011-6537 or 2011 TNT 61-28.
71
See: David Fisher (Siemens Healthcare) comments at Public Hearing on Proposed Regulations 26 CFR
Part 48 “Taxable Medical Devices” [REG-113770-10] (May 16, 2012) unofficial transcript available at
TAX ANALYSTS, Doc 2012-2232 or 2012 TNT 24-20.
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The same analysis underpins the proposed regulations preamble when the
Treasury excludes “warranties paid at the purchaser’s option” from the otherwise taxable
medical device sales price under IRC §4216(a) and Treasury Regulation §48.4216(a)–1.
There is a considerable value that can escape tax by structuring intercompany
transactions in this manner. As Dean Zerbe at the Alliantgroup points out:
Medical devices can be subject to extensive servicing and software
updates. Proper operation of certain medical devices requires long-term
and supplemental technician training. Such future servicing is comparable
to a warranty for replacement parts, and manufacturers wishing to provide
purchasers with a warranty covering software updates, physical servicing
(including calibration), and/or supplemental training would benefit from
greater clarity.72
Conclusion – Unanswered Question (2)
It is not clear how the IRS will respond because there are revenue and policy
implications in answering the related party pricing issue:
Revenue: If widely applied, Revenue Ruling 80-273 could potentially reduce the
MDET tax base by 25% by structuring related party transactions so that valuable services
and software are added after the MDET is imposed.
Policy: From a policy perspective, the question is whether the constructive price
rules currently in place, and developed more than twenty years ago for commodity
pricing (sport fishing equipment, archery equipment, coal, tires, gasoline guzzling
automobiles, and vaccines), achieve the right result in the high-technology medical
device market? Should federal income tax transfer pricing rules under IRC §482 apply to
the MDET as AdvaMed has suggested73?
Unanswered Question (3) – Title Passage
The Chapter 32 manufacturers’ excise taxes are all taxes on goods sold, rather
than taxes on services. Taxes on goods sold typically look to the title passage rules
adopted for the core definitions on all these taxes. Under these rules, a sale is defined as:
72

Dean Zerbe (Alliant group), Letter: Comments to REG-113770-10, Taxable Medical Devices (May 7,
2012) at 3, available at: TAX ANALYSTS, Doc 2012-9980 or 2012 TNT 93-84, Group Suggests Changes to
Proposed Regulations on Medical Device Excise Tax.
73
AdvaMed (the Advanced Medical Technology Association) Stephen J. Ubl, Letter responding to Notice
2011-89’s request for comments specifically on §4191(b)(2)(D), March 22, 2011, at 16 available at TAX
ANALYSTS, Doc 2011-6160 or 2011 TNT 58-12, available at TAX ANALYSTS, Doc 2011-6160 or 2011
TNT 58-12.
AdvaMed recommends that the IRS adopt, within the limits of what the statute permits, a
constructive pricing regime that recognizes the highly competitive nature of the industry,
the high degree of product differentiation, and complexity of the industry's distribution
network. That regime should maintain the objective of the existing constructive price
regime, i.e., to identify a constructive price equal to the fair market price that would be
paid by an independent wholesale distributor. That regime should allow the industry to
rely on the existing well- developed body of arm's length pricing principles in the Federal
income tax law without the development for purposes of the excise tax of rigid regulatory
formulas. (emphasis added)
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“an agreement whereby the seller transfers the property (that is, the title or
the substantial incidents of ownership) in goods to the buyer for a
consideration called the price, which may consist of money, services, or
other things74.
The proposed regulations for MDET make no changes to this sales definition nor
do they change any of the other title / goods-centric definitions contained in Chapter 32.
The proposed regulations preamble state:
Generally, the manufacturers excise tax attaches when the title to the
taxable article passes from the manufacturer to a purchaser. When title
passes is dependent upon the intention of the parties as gathered from the
contract of sale and the attendant circumstances.75
Changes at this point might have indicated that Treasury understood MDET to be
a fundamentally different manufacturer tax than had previously been the case under
Chapter 32. Justification for a change could have come through differentiating hightechnology manufacturing from traditional commodity manufacturing but the Treasury
does not appear to be making that decision76.
The consequences in casting the MDET as a traditional manufacturers tax, on
goods with title passage determining the tax point, is that issues involving over-reaching
and under-reaching arise. The MDET over-reaches when transactions are taxed that do
not seem to be the proper object for the excise tax such as charitable donations, samples,
demonstration products, products provided for evaluation, loaned instruments, and test /
development products. The MDET also under-reaches when very significant services
and software products integral to the high-tech medical devices functioning are carved
from the tax base such as software that is critical for initial use, continuing software
updates, and optional service and warranty agreements.
Over-reaching - The proposed regulations preamble specifically reference
Revenue Ruling 72-56377 which holds that providing taxable products free of charge for
promotional purposes are taxable for Chapter 32 purposes78 because title passes and there
is consideration in kind.
74

Treasury Regulation §48.0-2(a)(5) (emphasis added). See also: Treasury Regulation §48.0-2(b)(1)
indicating that manufactures excise taxes attach when title to the article sold passes from the manufacturer
to a purchaser
75
Proposed Treasury Regulation §§48.4919-1 and 48.4919-2 (preamble)
76
For example, the proposed regulations do not alter the installment sales and lease definitions. An
installment sale remains a contract with “title reserved in the seller, or under a conditional sale contract,
chattel mortgage arrangement or other arrangement creating a security interest [in the seller] …” [Treasury
Regulation §48.4216(c)-1 (emphasis added)]. A lease “means a contract or agreement, written or verbal,
which gives the lessee an exclusive, continuous right to the possession or use of a particular article for a
period of time.” [Treasury Regulation §48.4217-1 (emphasis added)].
77
1972-2 C.B. 568
78
Under Revenue Ruling 72-563, a gasoline and lubricating oils producer furnishes products ‘free of
charge’ (within its advertising and sales promotion program) to a stock car operator for his use in stock car
races. In return, the recipient agreed to display the producer's identifying trademark and other promotional
material in such a manner as to indicate his using the producer's products for racing purposes.
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But what if a dental device manufacturer makes donations to a volunteer program
such as Give-Kids-A-Smile or the Missions of Mercy, valued at more than $1.6 billion a
year79? Title passes from the manufacturer to dental volunteers and then to patients for
the donated medical devices. There is also an indirect promotional benefit in kind to the
manufacturer (goodwill developed with certain dentists). Does Revenue Ruling 72-563
indicate that this donation is taxable under the MDET? Plain reading the ruling seems to
indicate the answer is “yes”. AdvaMed made similar comments in a broader context:
Medical device companies commonly support disaster relief and similar
charitable missions through the donation of medical devices. For
example, many companies contributed volumes of medical device
products to support Hurricane Katrina relief. Sometimes these products
are provided to volunteer U.S. healthcare professionals engaged in
charitable missions for people in crisis in the U.S. and abroad. Product
donations for bona fide charitable purposes should not be subject to the
Medical Device Tax as a taxable use.80
Under-reaching - In March 2010 the Staff of the Massachusetts Medical Devices
Journal set out to check how accurate was the $20 billion revenue estimate ($2 billion per
year for 10 years) the Congressional Research Service provided for the MDET81. Using
gross revenue figures from medical device companies in the US market and isolating
sales from companies with multiple product lines as best as possible, they concluded:
The 57 companies we looked at would have generated about $1.87 billion
in excise taxes last year [2009], had the law been in effect then. That’s on
track to meet the prediction that the tax will generate $20 billion over 10
years, once it goes into effect in 2013.82
Did the Congressional Research Service assume, as the Massachusetts Medical
Devices Journal apparently did, that the full final price paid for medical devices, goods
and related services, was subject to the MDET? Gross sales figures undoubtedly include
the value for software and services commonly sold in conjunction with tangible medical
devices.

79

See: Academy of General Dentistry (and others), Letter: Internal Revenue Service Notice of Proposed
Rulemaking, Taxable Medical Devices REG-113770-10 (May 7, 2012) at 4, available at TAX ANALYSTS,
Doc 2012-9985 or 2012 TNT 93-89, Dentistry Groups Comment on Proposed Regulations on Medical
Device Excise Tax.
80
AdvaMed (the Advanced Medical Technology Association) Stephen J. Ubl, Letter responding to Notice
2011-89’s request for comments specifically on §4191(b)(2)(D), March 22, 2011, at 4 available at TAX
ANALYSTS, Doc 2011-6160 or 2011 TNT 58-12.
81
Janemarie Mulvey of the Congressional Research Service indicates that MDET should raise $20 billion
over ten years, in Health-Related Revenue Provisions in the Patient Protection and Affordable Care Act
(PPACA) R41128 (February 10, 2011) at 6.
82
Staff of Massachusetts Medical Devices Journal, Medical device tax would mostly hit the biggest firms,
MEDCITY NEWS, March 24, 2010, http://www.medcitynews.com/2010/03/medical-device-tax-wouldmostly-target-the-biggest- companies/.
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If software and services can be separated from the tangible medical device as set
out in the Rocen and Gerson hypothetical above83, then the MDET’s tax yield may be
much lower than projected. By not reaching this value, the regulations appear to be
under-reaching.
If Congress intended MDET to include in the tax base both the hardware and
right-to-use license for embedded object code medical device software, then the
regulations need to define a sale to include the (a) hardware components based on title
passage and (b) software components on right-to-use software licenses because software
is not captured under the title passage rule.
Because the proposed regulations do not contain language that could include
right-to-use software licenses, the medical device industry argues that MDET does not
tax the medical device software value if the software is incorporated into the device after
the manufacturing process is completed. For example the Medical Imaging and
Technology Alliance emphasized at the May 16th hearings that,
the long lifecycle and high technology nature of [medical devices
manufactured by medical imaging, radiopharmaceutical and radiation
therapy manufacturers] typically offer customers a service contract which
is voluntary and separate from the purchase of the device. In the course of
such servicing by the manufacturer, replacement components may be
installed in the medical imaging or radiation therapy systems. Clearly a
service contract is not an FDA listed device and thus, is not a taxable
medical device.
… similarly, we request clarification that upgrades to the software of
overall FDA listed devices should not be subjected to tax because the
software is not listed and is a component of the overall listed device.84
Paul A. Smith, representing McKesson Technology Solutions, made similar
observations that title to medical software does not transfer. Licensing agreements are
drafted independent from the device sale. These agreements are non-exclusive, nontransferrable contracts that the FDA does not define as a medical device under §201(h).
Smith indicated that based on the way that McKesson does business,
… medical software is licensed, not sold, to a customer via a nonexclusive
license agreement. Customers may also obtain optional information
technology (IT) services from McKesson for software installation on its
systems. Additionally, customers may sign an optional maintenance
agreement whereby McKesson maintains and updates the software. These
agreements may be part of the license agreement, or may be a separate
agreement.
Licensed software is either provided to customers under a
perpetual software license (the right to use the software indefinitely) or a
83

Rocen and Gerson, supra notes 67 and 70
David Fisher, Siemens Healthcare comments on the Medical Imaging and Technology Alliance behalf at
Public Hearing on Proposed Regulations 26 CFR Part 48 “Taxable Medical Devices” [REG-113770-10]
(May 16, 2012) unofficial transcript available at TAX ANALYSTS, Doc 2012-2232 or 2012 TNT 24-20.

84

19
Electronic copy available at: https://ssrn.com/abstract=2086594

MDET as a VAT
Ainsworth, Shact & Wasylyshyn
13 July 2012

term software license (the right to use the software for a fixed period of
time) … title to the software does not transfer and the license is indefinite
and non-exclusive.
McKesson arrangements may also include maintenance contracts
related to perpetual software licenses. The maintenance contracts are for a
specific period of time and are generally renewable annually. Such
maintenance contracts include providing upgrades, new releases, patches
that correct software programming bugs, software information updates,
new computer code enhancements, and corrections to programming errors
in the software or interface, as well as transportation, delivery, insurance,
IT and help desk services. The maintenance contract may be optional;
McKesson may not require the customer to purchase the maintenance
contract in order to license the medical software. …
The licensing of software via nonexclusive license agreements and
the treatment of IT services and maintenance does not fit squarely within
the rules related to sales or leases. Accordingly additional guidance is
requested.85
Conclusion – Unanswered Question (3)
It is not clear how the IRS will respond to the issues developed around the
Chapter 32 title passage rule and once again there are revenue and policy implications.
Revenue - It seems unlikely that the $20 billion revenue projection for the MDET
can be met if the goods-only, Chapter 32 title passage rules are followed.
Policy - The MDET is not an original provision in the PPACA but rather replaced
the §9009 fee contained in an earlier PPACA Senate version. Under §9009, a two billion
dollar annual fee was established applicable to the country’s largest medical devicemanufacturers86. This is not only the MDET’s stated revenue goal, but based on the
Massachusetts Medical Devices Journal study, the same medical device manufacturers
would be the primary taxpayers. Only the method for determining the tax was supposed
to change87. Because the fee reached both goods and services, should we assume that the
85

Paul A. Smith, (McKesson Corporation), Letter: Comments on Proposed Regulations for the Medical
Device Excise Tax (May 7, 2012) at 3-4, available at: available at TAX ANALYSTS, Doc 2012-9989 or
2012 TNT 93-93 Company Requests Clarification in Proposed Regulations on Medical Device Excise Tax.
86
The §9009 fee was set at two billion dollars from 2011 through 2017. After 2017 it was slated to
increase to three billion dollars. Joint Committee on Taxation referenced estimates (March 20, 2010, JCX17-10) Janemarie Mulvey of the Congressional Research Service indicates that MDET should raise $20
billion over ten years, in Health-Related Revenue Provisions in the Patient Protection and Affordable Care
Act (PPACA) R41128 (February 10, 2011) at 6. Note however, that the Treasury Department has a higher
estimate of $30 billion over the 2013-2022 period. Office of Management and Budget, Budget of the U.S.
Government, Fiscal Year 2013, Analytical Perspectives, at 224.
87
The fee was allocated across the industry based on market share and would not apply to companies with
medical device US sales below five million dollars. [§9009(b)] The fee did not apply to Class I or Class II
products sold to consumers at retail of no more that $100 per unit. [§9009(d)(1)] As a result pregnancy
tests, contact lenses, and blood pressure monitors were exempt. The principle behind imposing a fee was
the belief that major medical device companies stood to benefit substantially from the PPACA and should
therefore be required to pay something extra.
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excise tax would reach the same values or should the change to the manufacturer’s excise
tax be presume to convey intent to exclude services?
(4) Unanswered Question – Objective Valuation
The MDET is not an invoice based tax. Although the invoice price may be the
starting point, most prices will be determined under the IRC §4216(b) and Treasury
Regulation §48.4216(b)-1 constructive price rules88 because this is how the medical
device market is structured89.
Thus, prices in most cases will be determined based on an objective valuation.
This means that the tax will be imposed on the fair market value for the items sold and
the actual price paid will be irrelevant. If the invoice price controlled, then valuation
would be subjective, that is, tax would be imposed on the amount the buyer is willing to
pay.
Under traditional manufactures excise taxes, constructive pricing is the exception
rather than the rule90 but under the MDET the exception has become the rule. This
makes the MDET both (a) an exceptionally complex levy, open to tax planning among
related parties, and (b) an exceptionally unfair tax when imposed on charitable donations,
or devices provide for demonstration, evaluation, test, and development purposes. These
results are unfortunately unavoidable under an objective valuation regime.
Complexity - The tax planning opportunities under the title passage rules have
been considered above. Corporate groups’ ability to structure sales among related parties
to reduce the impact of the MDET is well understood91.
Even without tax planning in mind, the constructive pricing objective valuation
approach brings with it considerable complexity because constructive pricing rules apply
on a product-by-product basis. They require access to industry-wide proprietary pricing
information or develop detailed device-by-device comparable wholesale prices. This
approach is neither practical nor feasible in a highly competitive, differentiated global
market92. AdvaMed argues that,
the determination of the price to which the tax attaches likely will be a
complex determination for many companies, large and small, across the
range of their product lines.
This determination and others (e.g., what constitutes a "sale", who
is the manufacturer, what devices are exempt from tax, what uses are
taxable and nontaxable) will require substantial analysis by companies on
88

See: text at supra note 58.
See: text at supra note 59.
90
Sport fishing equipment, archery equipment, coal, tires, gasoline guzzling automobiles, and vaccine
manufacturers are normally selling to independent third party distributors, not wholly owned service or
sales subsidiaries as is the case in the medical device market.
91
See: text from supra note 80 to supra note 85.
92
AdvaMed (the Advanced Medical Technology Association) Stephen J. Ubl, Letter responding to Notice
2011-89’s request for comments specifically on §4191(b)(2)(D), March 22, 2011, at 17 available at TAX
ANALYSTS, Doc 2012-9995 or 2012 TNT 93-99.
89
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a device-by-device basis and the development of recordkeeping systems
consistent with those determinations. The basic premise of the
constructive price rules, that the tax should be determined based on a price
that represents an arm's length fair market price.93
With respect to the timing for booking rebates and discounts, constructive pricing
will require recordkeeping systems inconsistent with Generally Accepted Accounting
Standards (GAAP) and International Accounting Standards (IAS)94.
Fairness - The consequences attributable to providing medical devices at no
additional charge under IRC §4216(b)(1)(C) and Treasury Regulation §48.4216(b)-2(e)
are clear. Title passage determines that a sale has occurred95 and the sale price is
determined via constructive pricing rules because the exchange was at less than fair
market value in a non-arm’s length transaction96. MDET is due on the fair market value
of the device.
Charitable donations, demonstration devices, medical devices provided for
evaluation purposes, and test or development products provided at no additional charge
are all subject to MDET. This outcome could, however, be avoided under subjective
valuation.
At the proposed regulations May 16th hearing, Christopher White from AdvaMed
put a medical device in a Ziplock bag and brought it through IRS security to make a
point. He passed the device around the hearing room and stated:
I would encourage you to open the bag and to kind of handle this, this is
an orthopedic implant from one of our fine orthopedic members, and it is
marked for demonstration purposes only, and this is to illustrate our first
priority issue concerning nontaxable uses.
As we state in our comments, there are many noneconomic uses of
medical devices, including samples, demonstration products, evaluation
products, and many others, and these are educational arrangements, there's
no consideration provided, there's no economic value. These are so that,
just as you can hold this medical technology and assess its unique features,
so can a patient, so can a doctor.
So we see that there's a value to having a patient feel and
understand the functionality, the range of motion and other unique features
of medical technology, and so a medical device company would provide a
demonstration unit or an evaluation product. And these are provided
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AdvaMed (the Advanced Medical Technology Association) Stephen J. Ubl, Letter: AdvaMed Comments
on Implementation of Medical Device Excise Tax Provisions of the Affordable Care Act, May 3, 2012, at 17
available at TAX ANALYSTS, Doc 2011-6160 or 2011 TNT 58-12.
94
Id., at 9
95
IRC §4191(a); Treasury Regulation §48.4191-1(a); Treasury Regulation §48.0-2(b)(1).
96
IRC §4216(b); Treasury Regulation §1.48.4216(b)(1).
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without charge. Under a reading of the proposed regulation, it could be
that these uses are deemed taxable.97
Conclusion – Unanswered Question (4)
It is not clear how the IRS will respond to the issues developed involving
objective valuation in the final regulations. There are revenue and policy implications.
Revenue - Objective valuation makes the MDET a very complex tax to comply
with and administer. It is difficult to determine if this complexity will produce a larger or
smaller revenue stream for the government and the net revenue (after deducting
compliance costs) may well be less than expected.
Policy - From a policy perspective, the MDET runs into fairness issues because it
taxes charitable donations at fair market value. While subjective valuation would solve
this problem, IRC §4216(b)(1)(C) is clear that an objective valuation is required when an
exchange is at less than fair market value in a non-arm’s length transaction.
MDET RECAST – A MARKET-SPECIFIC VAT
The MDET, like the former New York HROT, is a single stage transaction tax
imposed in a limited, clearly defined market98. Despite this similarity, these taxes are
very different because the MDET is imposed on the manufacturer (at the commercial
chain summit) while the former New York HROT is imposed on the final consumer (at
the commercial chain abyss). Consumers bear the HROT’s full burden while the intent is
for manufacturers to bear the MDET’s full weight99.
Converting a consumption tax like the HROT to a standard European style VAT
is easy to imagine. Value can be taxed as it is added at each stage along the commercial
chain until the transaction sequence reaches the final consumer. The tax can be withheld
in slices and remitted in full when final consumption occurs.
Converting the MDET to a VAT, however, is more difficult to imagine. We want
the tax determined and due when manufacturing ends, which is not necessarily when
consumption begins. Neither the institutional consumer such as hospital chains, nursing
homes, health maintenance organizations, and other large-scale institutional healthcare
users nor the individual consumer at retail is supposed to pay the tax. In fact, the tax is
supposed to be completely removed when individual consumers make purchases for
personal consumption. A VAT can do this, but the design will not be standard.
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Christopher White (AdvaMed) Public Hearing on Proposed Regulations 26 CFR Part 48 “Taxable
Medical Devices” [REG-113770-10] (May 16, 2012) unofficial transcript available at TAX ANALYSTS,
Doc 2012-2232 or 2012 TNT 24-20.
98
The HROT market is entire room accommodation market in the State of New York. The MDET market
is any device as defined the Federal Food, Drug, and Cosmetic Act section 201(h) intended for humans.
99
The Federation of American Hospitals made the case that the MDET regulations needed to contain
provisions that would prevent manufacturers from passing this tax through to customers. It is difficult to
see how this could be accomplished. Federation of American Hospitals (and others), Letter: Notice of
Proposed Rulemaking and Notice of Public Hearing on Taxable Medical Devices (77 Fed. Reg. 6.028 [Feb.
7, 2012]) at 3-5.
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Policy Background
Tax policy should guide tax design. MDET’s policy concerns are derived from its
origin as a funding provision for the PPACA. MDET reflects health care stakeholders
effort to “share responsibility” for implementing healthcare reform100. MDET is intended
to “bring in” the medical device manufacturing industry’s contribution.
This funding provision began as a targeted $4 billion fee over 10 years101 and the
amended PPACA Senate version §9009 increased this fee to $20 billion over 10 years102.
Both fees targeted the largest medical device manufacturers. This was perceived to be
unfair so the provision was converted to the current broad-based 2.3% excise tax.
The problem with an excise tax solution is that traditional manufacturer excise
taxes do not successfully secure an industry-wide contribution. They are quite narrow.
They focus on the last manufacturer rather than all manufacturers in a chain and they
tend to be concerned with simple commodity-type goods rather than high technology
devices that rely on software and services to deliver a completed product.
The excise tax model is not a good fit for Congress’s intent so adjustment is
warranted. Congress wanted a transaction tax that would fairly assess the manufacturing
segment output in the medical device supply chain at 2.3% of sales. The underlying
concept is that this contribution (tax) would be proportional to the increase in benefits
(sales) that device manufacturers were expected to realize from healthcare reform.
Recasting MDET
Recasting the MDET is not difficult. Two changes are needed. First, the MDET
needs to be applied to each taxable medical device sale and to the sale of each discrete
component of a taxable medical device within the manufacturing segment of this
commercial chain. Secondly, the tax must be imposed on the increase in price
(subjectively valuation) as the medical device passes through the commercial chain.
The proposed revised statute would read as follows [additions in italics; omissions
crossed out]:
100

Senator Max Baucus, Chair of the Senate Finance Committee, Letter to President Obama, (November 6,
2008) available at: http://www.finance.senate.gov/newsroom/chairman/release/?id=b7fe3588-4028-4484b0fd-f4c90632db36
Shared Responsibility: Individuals, employers, and the government must all play a part in
the creating and funding of a new health care system. I intend to enumerate specific roles
and opportunities for all to share the burden.
101
Senate Finance Committee, Framework for Comprehensive Health Reform (September 9, 2009) 18,
available at: http://www.himss.org/content/files/SenateFrameworComprehensiveHealthReform.pdf
102
The §9009 fee was set at two billion dollars from 2011 through 2017. After 2017 it was slated to
increase to three billion dollars. Referencing estimates by the Joint Committee on Taxation (March 20,
2010, JCX-17-10) Janemarie Mulvey of the Congressional Research Service indicates that MDET should
raise $20 billion over ten years, in Health-Related Revenue Provisions in the Patient Protection and
Affordable Care Act (PPACA) R41128 (February 10, 2011) at 6. Note however, that the Treasury
Department has a higher estimate of $30 billion over the 2013-2022 period. Office of Management and
Budget, Budget of the U.S. Government, Fiscal Year 2013, Analytical Perspectives, at 224.
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§4191 Medical devices
(a) In general
There is hereby imposed on the sale of any taxable medical device by each the
manufacturer, producer, or importer a tax equal to 2.3 percent of the price for
which so sold or in the case where a device or portion of a device is resold among
a manufacturers, producers, or importers, the increase in price, as invoiced.
(b) Taxable medical device
For purposes of this section—
(1) In general
The term ‘‘taxable medical device’’ means any device or portion of a
device (as defined in section 201(h) of the Federal Food, Drug, and
Cosmetic Act) intended for humans.
(2) Exemptions
Such term shall not include—
(A) eyeglasses,
(B) contact lenses,
(C) hearing aids, and
(D) any other medical device determined by the Secretary to be of
a type which is generally purchased by the general public at retail
for individual use.
The recast MDET recognizes that there are multiple manufacturers in a single
commercial chain and each manufacturer contributes to the whole. The “manufacturer”
definition in the regulations will be broadly construed.
A manufacturer will include goods providers including those providing parts,
replacement parts, components, sub assemblies103 and services including warranties,
training, software, software updates. A medical device will be defined to mean a fully
functional, operational, updated, and subsequently modified medical device that qualifies
as a device under section 201(h). A taxable medical device will be defined as any final
device, device part, replacement part, component, sub assembly, warranty, training,
software, software update necessary to make a medical device.
103

David Fisher at Siemens Healthcare, speaking on the Medical Imaging and Technology Alliance behalf
went to great lengths to emphasize that the manufacturing supply chain was exceedingly complex,
involving multiple partially completed device sales and component acquisitions.
As a general matter [imaging and radiation therapy equipment] are very large machines
with many components. As many as a thousand, thousands at times. … [There are]
complex corporate and manufacturing structures to facilitate global sales. In some cases,
dozens of corporate affiliates manufacture different medical devices or components,
transferring components to each other for incorporation into finished products, and then
transferring the finished product among each other again. In other cases components may
just be purchased from third party vendors.
Public Hearing on Proposed Regulations 826 CFR Part 48 “Taxable Medical Devices” [REG-113770-10]
(May 16, 2012) at 8, unofficial transcript available at TAX ANALYSTS, Doc 2012-2232 or 2012 TNT 24-20.

25
Electronic copy available at: https://ssrn.com/abstract=2086594

MDET as a VAT
Ainsworth, Shact & Wasylyshyn
13 July 2012

It will be clear in the regulations that any article (tangible good, service or
software supplied) that is necessary for a medical device to achieve or maintain
certification under the Federal Food, Drug, and Cosmetic Act is included within the
taxable medical device definition.
Procedural regulations will explain that the MDET will be charged on the invoice
price (subjective valuation) for every transaction a manufacturer made. In cases where a
manufacturer:
(a) purchases a taxable medical device (component) from another party, and then
(b) integrates this component into another (larger) medical device, and finally
(c) sells the completed device onward, that
(d) the tax will be due on the increase in value between the purchase price (a) and
the onward sale price (c).
The tax due will be identified, but not “passed though” to the buyer on each invoice.
For example, if X sells a taxable medical device to Y for $100 and Y incorporates
it into another medical device who sells the larger device to Z (a hospital that will use the
medical device to provide care, and is not a manufacturer) for $1,000, then:
 X will determine a $2.30 tax on its $100 sale and note tax paid on the invoice.
The tax does not “pass-through” to Y. The invoice will be for $100. X will also
provide its tax ID number.
 Y will determine a $23.00 tax on its $1,000 sale, deduct $2.30 based on X’s
invoice note, leaving $20.70 due. The invoice from Y to Z will be for $1,000 but
will record the $20.70 due and the $2.30 already paid. The tax ID numbers for
both X and Y will be provided on the invoice.
 If X does not record the $2.30 on the invoice or if X does not provide a tax ID
number, then Y will not be allowed a deduction and will owe the full $23.00 tax.
 If the invoice Y issues to Z (a hospital that is not a manufacturer) does not include
X’s tax due note and Y’s tax due along with their tax ID numbers then Z will treat
the invoice as “tax inclusive.” Z will be required to withhold the tax from its
invoice payment. Most likely a corrected invoice will issue, if not then after a
period of time Z will be required to remit the tax withheld (perhaps on its annual
income tax return). It will be clear that Z does not bear the tax burden.
The exemption under IRC §4191(b)(2)(D) will be streamlined under the recast
MDET. Rather than a difficult product exemption exercise under the current law, it will
not be necessary for the Secretary to determine that a medical device is “of a type which
is generally purchased by the general public.” The recast MDET allows exemptions to be
more precisely targeted so the exemption can be applied to “purchases by the general
public at retail for individual use.”
A further procedural regulation example substitutes ZZ (a retail pharmacy) for Z
(the hospital) in the example used above. The requirement is to remove the MDET from
the entire commercial chain. ZZ will be required to provide certification that the
purchase was for resale to the general public for individual use”.
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Assume the same facts as in the prior example (except ZZ – a retail pharmacy – is
substituted for Z). X sells a taxable medical device to Y for $100, and Y incorporates it
into another medical device and then sells the larger device on to ZZ (a retail pharmacy)
for $1,000, then:
 X will determine a $2.30 tax on its $100 sale, noting this on the invoice. The tax
does not “pass-through” to Y so the invoice remains at $100 and X provides its
tax ID number on the invoice.
 Y will determine a $23.00 tax on its $1,000 sale, deducting $2.30 based on the
note on X’s invoice, leaving $20.70 due. Y’s invoice to Z will be for $1,000,
recording both the $20.70 due and the $2.30 already paid and both X and Y’s tax
ID numbers are provided on the invoice.
 If Y’s invoice to ZZ notes both X’s and Y’s tax due along with their tax ID
numbers, then ZZ submits this record (taxes due and tax ID numbers) to the IRS
and no withholding by ZZ will be required.
 If, however, the invoice Y issues to ZZ does not note X’s tax due, and Y’s tax due
along with their tax ID numbers, then ZZ will treat the invoice as “tax inclusive”.
ZZ will be required to withhold the tax from the invoice payment.
 Once the IRS receives from ZZ the taxes due from X and Y along with their tax
ID numbers, the IRS will (a) confirm the tax received from X ($2.30) and Y
($20.70) and (b) deem these amounts to be an MDET pre-payment that can either
be used to offset other taxes due or be refunded. A notice will issue from the IRS.
The recast MDET will be self-enforcing, flexible, and will solve the major issues
currently facing the MDET: (1) a double taxation possibility, (2) related party pricing and
the application of constructive pricing rules, (3) manipulation of values through exclusion
of service / software attributes in the title passage rules, and (4) unfairness in forced
application of objective valuation rules for charitable donations, educational uses, testing
or no-cost replacement parts.
Double taxation is removed from the recast MDET because values are taxed in
slices as they are added to the medical device, not absolutely on full value whenever a
sale by a final manufacturer occurs. The tax is imposed throughout the commercial
chain, as value is determined, not on the difficult to identify “last manufacturer” in line.
Constructive pricing will not apply under the recast MDET. Tax is imposed on
the invoice price (the price the buyer pays) rather than a difficult to determine fair market
value or what the medical device is worth on the open market under the same or similar
circumstances of sale.
The incentive to migrate supply chain activities, placing services and software
values outside the taxable base, is also eliminated once the definition of taxable medical
device is expanded to include any device or portion of a device. This provision is not
only designed to allow the MDET to be collected in slices, but it prevents goods-based
distortions in the medical device’s true value. The tax base Congress intended to tax was
the completed medical devices sales, not just the tangible property component.
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Finally, the unfairness inherent in placing a tax on medical devices that for
whatever reason are donated or contributed at no charge can also be eliminated. It is a
simple matter to connect the charitable donations to sales at retail (as in the ZZ example
above). The Red Cross or Katrina relief fund would simply need to be presented a “no
charge” invoice and the tax is removed. It simply extends subjective valuation to indicate
that if a final transfer is made for no consideration that the entire tax on prior slices in the
manufacturing chain should be exempt. The ZZ example should be followed again.
CONCLUSION
MDET can be recast and made largely self-enforcing if it was approached as a
multi-stage transaction tax with subjective rather than an objectively valued excise tax. A
manufacturers excise tax simply does not fit in a high technology manufacturing sector
like medical devices.
Although this paper has approached recasting the MDET by changing the statute,
the same result could be achieved under the current statute through regulatory measures.
That exercise has not been included here because doing so would significantly extend the
text. The key to making this change through regulations would be to clearly articulate the
tax policy objectives underpinning the MDET. An assessment of the medical device
market would be necessary and it would be necessary to reach a conclusion that a multistage transaction tax is the best way to meet Congressional needs.
Action is needed before the final regulations are issued. There are at least four
major areas where revenue and policy objectives may be in conflict and administrable
solutions are needed. The overriding administrative advantage in recasting the MDET as
a market-specific VAT is that it can be fully automated with off-the-shelf tax software
applications in use today. These applications were designed for the VAT.
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